THOMAS M. SANDVIK

Results-driven marketing leader with over 25 years of experience, recognized for exceptional leadership skills, strategic planning, and customer needs analysis. Specializing in product lifecycle management, institutional environment knowledge, and establishing partnerships with Key Opinion Leaders. Highly regarded by colleagues and supervisors as a valuable asset to both the organization and clients. Demonstrated success in planning and executing effective short-term and long-term strategic plans, consistently advancing in roles and responsibilities. Skilled in strategic planning, project management, product launches, and stakeholder communication to optimize operations and drive team achievements. Seeking a role to apply expertise in strategic planning and project management to lead diverse teams in delivering impactful initiatives that enhance patient outcomes, while excelling in stakeholder engagement and operational effectiveness.

• 2019 launched Len/pembro in aEC
• 2018 finished 6 in nighingale out of 21, top Central ICAM, launched Lenvima in HCC
• 2018 Selected Renal/Lung, 10 Regional Leadership Council
• 2017 Selected to Pfizers Masters Program recognizing Sales achievement and tenure
• Selected as trainer for Pfizer 2013 reorganization.
• Selected P4 training/coaching initiative.
• Led Celebrex State Medicaid Formulary team which saw additional clinical criteria added to support Celebrex.
• Led Lyrica and Exubera State Medicaid Formulary strategies which saw Lyrica added to state PDL.
• Pfizer Management Development program, Pfizer Guest Trainer program, Advanced Sales Training.
• Developed plan to implement Field Based Medicine national initiative within district. Plan execution led to highest response rate in region by targeted physicians.
• Initiated multi level, multi department strategy that had Zyvox placed 1st line on NP protocols at Froedtert Hospital. All IV will be switched to PO Zyvox ASAP.
• Spearheaded Celebrex speaker development program that resulted in Celebrex sales increase of 6.73% for district. This was the largest increase in the Midwest region 2003.
• Trained / Mentor new sales representatives as well as IHR, TSR representatives throughout career.
• Implemented plans and led teams that gained formulary approvals for Glyset at Dean Health Plan, Physicians Plus and for Detrol at United Health Plan.
• Elected to regional advisory panel by peers 2007.
• Field Manager Clean Water Action Lobby 1988-1990.

• 2016 Regional Performance Fund winner for Ibrance and Sutent Attainment. Top 20% of Sales force
• Currently responsible for Sutent, Inlyta, Torisel, Xalkori and Bavencio
• Launched Bavencio Immuno-Oncology agent in Metastatic Merkel Cell and Metastatic Urothelial Cancer
• Launched Ibrance in Metastatic Breast Cancer 2016
• Designed and implemented statewide Investing in You Initiative training at POA meeting.
• 2013 worked to open access at major accounts leading to new policy at Advanced Pain Management. Leveraged relationships to positively impact statewide Medicaid business for Eliguis.
• 2012 finished #3 overall in the Midwest region. Exceeded quota on both key products. Attainment of 111.27 Rated SE.
• 2011 finished in the top 1/3 of DSN group, exceeded quota on both Celebrex and Lyrica.
• 2010 Finished #2 B side TSR in the State and #4 overall with 104.57% attainment. Rated SE
• 2009 Celebrex award winner Celebrex contest.
• 2008 Lyrica award winner #2 in region Go Vertical Contest.
• 2007 Lyrica award winner #2 in region Power Surge Contest.
• 2007 National convention award winner.
• 2006 Lyrica new product launch 150% to goal. Top volume in Midwest. Top 1/3 in area for 2005.
• 2005 District Leadership Award.
• 2005 MVP THR regional POA 2.
• 2005 Moved from 5% to21 on GAR based on Zyvox protocols.
• 2005 Celebrex Force of One winner top GAR movement for Celebrex.
• 2005 Drove Celebrex market share +8.92 points winner of “Sprint to the Finish” campaign.
• 2004 Convention Award winner Vfend.
• 2004 Member District of the Year winner.
• 2003 #1 IHR in region for Zyvox. 134% attainment. #13 in division, December GAR.
• 2003 #1 IHR in region for Vfend. 241.5% attainment. #17 in division, December GAR.
• 2003 Convention Award winner Zyvox.
• Celebrex/Bextra sales increased from 144% of goal to 250% through December 2002.
• Voted Most Valuable teammate by peers(sales leadership, peer consultancy, peer leadership, teamwork) 6/02.
• Voted Most Valuable teammate by peers(sales leadership, peer consultancy, peer leadership, teamwork) 1/03.
• Winner of Rookie of the Year Award 2002.
• Winner of district Zyvox marketshare contest 9/02.
• National Sales Award Winner, top 10% of sales force 2001.